Trial Profile
Phase IIb Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of ARX201 Following Repeated Dosing to Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Somatropin (Primary)
- Indications Somatotropin deficiency
- Focus Therapeutic Use
- Sponsors Ambrx
- 22 May 2014 New trial record